Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
Summary not available.
Canopy Growth Corporation (CGC) announced on June 29, 2022, that it entered into Exchange Agreements with certain holders to acquire approximately C$255.4 million of its 4.25% unsecured convertible senior notes due 2023. The transaction includes the issuance of Canopy Shares and C$3 million in cash for accrued interest. Constellation Brands' subsidiary, GCILP, will acquire a minimum of 21.9 million Canopy Shares. The transaction is structured to comply with securities regulations and is not deemed to require approval from minority shareholders.
Canopy Growth Corporation (CGC) reported its financial results for Q4 and FY2022, showcasing a net revenue of $520 million, down 5% year-over-year. Despite a 25% revenue decline in Q4 versus the previous year, the company maintained its #1 share in the premium flower category. Plans to acquire Wana Brands and Jetty Extracts were announced, targeting growth in the U.S. and Canada. The net loss for FY2022 was $320 million, while adjustments for EBITDA losses reached $415 million. Management aims for adjusted EBITDA positivity by FY2024.
Canopy Growth Corporation (NASDAQ: CGC) has introduced new products across its brand portfolio, including 7ACRES, Ace Valley, Deep Space, and Doja, just in time for summer. Highlights include the premium flower offering, Doja 91K 14g, and new infused pre-rolls. Innovations like Ace Valley's recyclable packaging and new beverage flavors from Deep Space aim to meet evolving consumer preferences. The new releases reflect Canopy's commitment to product innovation and leadership in the premium cannabis market.
Canopy Growth Corporation (CGC) has announced a strategic agreement to acquire Jetty Extracts, a leading California cannabis brand, which specializes in solventless vape technology. The acquisition rights will be exercised upon federal legalization of THC in the U.S. or earlier at Canopy’s discretion. Canopy plans to purchase approximately 75% of Jetty for about $69 million, mainly through stock. This move aims to strengthen Canopy's U.S. THC ecosystem, leveraging Jetty's market share and innovative extraction technologies, while also exploring expansion into Canada.
Canopy Growth Corporation (CGC) will release its financial results for Q4 and fiscal year 2022 on May 27, 2022. The release will occur before market open, and a subsequent audio webcast featuring CEO David Klein and CFO Judy Hong will take place at 10:00 AM ET the same day. For the first time, shareholders can engage via a Q&A platform managed by Say Technologies, opening on May 20 and closing on May 26. The company has a strong market presence, offering diverse cannabis products, including oils and edibles, and is partnered with Constellation Brands.
Canopy Growth Corporation (CGC) announced strategic initiatives aimed at reducing costs and enhancing profitability, targeting savings of $100-$150 million within 12-18 months. Key actions include reducing cost of goods sold (COGS) through improved efficiency, implementing flexible manufacturing, and streamlining indirect costs. The company anticipates charges of $250-$300 million in Q4 FY2022 primarily due to non-cash impairments. Management emphasizes the critical need for these changes to align with market realities and support long-term growth.
Canopy Growth Corporation (CGC) announced key leadership appointments to bolster strategic growth and execution for FY23. Judy Hong becomes Chief Financial Officer, bringing over 20 years of financial experience, while Jonathan Di Tosto steps in as Chief Operations Officer, focusing on optimizing the supply chain. Four new strategic roles were created in the Senior Leadership Team to enhance U.S. operations, leveraging partnerships with Constellation Brands. CEO David Klein emphasized the importance of this new leadership structure as Canopy aims for increased profitability and market positioning.
Canopy Growth Corporation (NASDAQ: CGC) announced positive results from a six-month clinical trial exploring the effects of cannabidiol (CBD) on menstrual-related symptoms. Conducted with James Madison University, the study involved 40 participants who received either 160mg or 320mg of CBD for 5 days each month. Results showed significant reductions in symptoms such as cramping, irritability, and stress. This research highlights the potential of cannabis-based therapies in managing menstrual health, paving the way for future studies on CBD's effects throughout reproductive life stages.
Benzinga announced that Canopy Growth CEO David Klein and Wana Brands CEO Nancy Whiteman will keynote the Benzinga Cannabis Capital Conference on April 20-21, 2022, in Miami, Florida. They will discuss effective strategies for entering the U.S. THC market amid evolving regulations. Klein emphasized building a robust U.S. ecosystem through partnerships, while Whiteman highlighted Wana's growth and innovative approaches. The conference promises extensive networking, a new expo floor, and opportunities for investment capital.